| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.9 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |